The Median Informs the Message: Accuracy of Individualized Scenarios for Survival Time Based on Oncologists' Estimates
Authors:
- Belinda E. KielyBKBelinda E. Kiely
- Andrew J. MartinAMAndrew J. Martin
- Martin H.N. TattersallMTMartin H.N. Tattersall
- Anna K. NowakANAnna K. Nowak
- David GoldsteinDGDavid Goldstein
- Nicholas R.C. WilckenNWNicholas R.C. Wilcken
- David K. WyldDWDavid K. Wyld
- Ehtesham A. AbdiEAEhtesham A. Abdi
- Amanda GlasgowAGAmanda Glasgow
- Philip J. BealePBPhilip J. Beale
- Michael JeffordMJMichael Jefford
- Paul A. GlarePGPaul A. Glare
- 1 October 2013
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 31 (28) , 3565-3571
Abstract
Purpose: To determine the accuracy and usefulness of oncologists' estimates of survival time in individual patients with advanced cancer. Patients and Methods: Twenty-one oncologists estimated the “median survival of a group of identical patients” for each of 114 patients with advanced cancer. Accuracy was defined by the proportions of patients with an observed survival time bounded by prespecified multiples of their estimated survival time. We expected 50% to live longer (or shorter) than their oncologist's estimate (calibration), 50% to live from half to double their estimate (typical scenario), 5% to 10% to live ≤ one quarter of their estimate (worst-case scenario), and 5% to 10% to live three or more times their estimate (best-case scenario). Estimates within 0.67 to 1.33 times observed survival were deemed precise. Discriminative value was assessed with Harrell's C-statistic and prognostic significance with proportional hazards regression. Results: Median survival time was 11 months. Oncologists' estimates were relatively well-calibrated (61% shorter than observed), imprecise (29% from 0.67 to 1.33 times observed), and moderately discriminative (Harrell C-statistic 0.63; P = .001). The proportion of patients with an observed survival half to double their oncologist's estimate was 63%, ≤ one quarter of their oncologist's estimate was 6%, and three or more times their oncologist's estimate was 14%. Independent predictors of observed survival were oncologist's estimate (hazard ratio [HR] = 0.92; P = .004), dry mouth (HR = 5.1; P < .0001), alkaline phosphatase more than 101U/L (HR = 2.8; P = .0002), Karnofsky performance status ≤ 70 (HR = 2.3; P = .007), prostate primary (HR = 0.23; P = .002), and steroid use (HR = 2.4; P = .02). Conclusion: Oncologists' estimates of survival time were relatively well-calibrated, moderately discriminative, independently associated with observed survival, and a reasonable basis for estimating worst-case, typical, and best-case scenarios for survival.Keywords
This publication has 33 references indexed in Scilit:
- Using scenarios to explain life expectancy in advanced cancer: attitudes of people with a cancer experienceSupportive Care in Cancer, 2012
- Development and Validation of a Prognostic Nomogram for Terminally Ill Cancer PatientsJNCI: Journal of the National Cancer Institute, 2011
- How Long Have I Got? Estimating Typical, Best-Case, and Worst-Case Scenarios for Patients Starting First-Line Chemotherapy for Metastatic Breast Cancer: A Systematic Review of Recent Randomized TrialsJournal of Clinical Oncology, 2011
- Advanced cancer patients’ prognostic information preferences: a reviewPalliative Medicine, 2008
- Disarming the guarded prognosis: predicting survival in newly referred patients with incurable cancerBritish Journal of Cancer, 2005
- A simple and accurate prediction model to estimate the intrahospital mortality risk of hospitalised cancer patientsInternational Journal Of Clinical Practice, 2004
- Prediction of survival in terminal cancer patients in Taiwan: constructing a prognostic scaleJournal of Pain and Symptom Management, 2004
- Cancer Patient Preferences for Communication of Prognosis in the Metastatic SettingJournal of Clinical Oncology, 2004
- A New Palliative Prognostic ScoreJournal of Pain and Symptom Management, 1999
- Survival Prediction of Terminally III Cancer Patients by Clinical Symptoms: Development of a Simple IndicatorJapanese Journal of Clinical Oncology, 1999